Cyclerion Therapeutics, Inc.
CYCN
$2.95
-$0.20-6.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -95.51% | 830.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -95.51% | 830.93% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -95.51% | 830.93% | |||
| SG&A Expenses | 20.35% | 0.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.94% | -1.36% | |||
| Operating Income | -390.24% | 144.50% | |||
| Income Before Tax | -369.62% | 173.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -369.62% | 173.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -369.62% | 173.31% | |||
| EBIT | -390.24% | 144.50% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -368.15% | 172.85% | |||
| Normalized Basic EPS | -368.15% | 172.83% | |||
| EPS Diluted | -368.15% | 171.90% | |||
| Normalized Diluted EPS | -368.15% | 172.83% | |||
| Average Basic Shares Outstanding | 0.55% | 0.63% | |||
| Average Diluted Shares Outstanding | 0.55% | 0.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||